We are live on ! Find out more

229 hedge funds and large institutions have $1.44B invested in Genmab in 2024 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 87 increasing their positions, 75 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital inflows, than outflows

Capital inflows: $131M | Capital outflows: $95.3M

16% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 75

8% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 39

1% more funds holding

Funds holding: 227 → 229 (+2)

0.21% more ownership

Funds ownership: 7.15% → 7.36% (+0.21%)

28% less call options, than puts

Call options by funds: $977K | Put options by funds: $1.36M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
229
Holders Change
+2
Holders Change %
+0.88%
% of All Funds
3.29%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
42
Increased
87
Reduced
75
Closed
39
Calls
$977​K
Puts
$1.36​M
Net Calls
-⁠$384​K
Net Calls Change
-⁠$1.2​M

GMAB Hedge Fund Activity: Q1 2024 in Review

229 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2024, worth a combined $1.44B — down 2.9% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new GMAB positions and 39 closed out — a net gain of 3 holders — while 87 added to existing stakes and 75 trimmed.

The largest buyer was Marshall Wace, adding an estimated $21.6M. The largest seller was Stifel Financial, cutting an estimated $12.9M.

  • 229 institutional investors held Genmab (GMAB) as of Q1 2024, up from 227 in Q4 2023.
  • Funds reported $1.44B of Genmab stock for Q1 2024, down 2.9% quarter-over-quarter.
  • 42 funds opened new Genmab positions in Q1 2024 and 39 closed out, a net change of +3 holders.
  • The largest Genmab buyer in Q1 2024 was Marshall Wace, an estimated $21.6M added.
  • The largest Genmab seller in Q1 2024 was Stifel Financial, an estimated $12.9M sold.

Based on aggregated 13F filings for Q1 2024.